10-Q · May 13, 2026
Genprex, Inc. reported a net loss of $4.46 million for Q1 2026, an increase of 13% from $3.96 million in Q1 2025. The company saw a rise in research and development expenses by 8% year-over-year, driven by clinical…
Earnings analysis · 10-Q
GNPX earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt contains no revenue, EPS, margin, balance-sheet, cash-flow, or segment figures, so quarterly operating trends cannot be assessed from the available filing text. The principal developments are…
Read full summary
The provided 10-Q excerpt contains no revenue, EPS, margin, balance-sheet, cash-flow, or segment figures, so quarterly operating trends cannot be assessed from the available filing text. The principal developments are continued remediation of material internal-control weaknesses and conditional Nasdaq compliance through December 7, 2026. Delisting risk remains material because the company must maintain a $1.00 bid price and may face immediate delisting if the $5 million MVLS rule becomes effective while market value remains below that threshold.
What stood out
-
Regained Nasdaq Bid-Price Compliance
On August 4, 2026, Genprex was notified that it had regained compliance with Nasdaq’s $1.00 minimum bid-price requirement, temporarily reducing immediate delisting risk.
-
Additional Financial Reporting Procedures
Management undertook additional analysis and post-closing procedures during the quarter ended June 30, 2026, and stated that the financial statements fairly present the company’s financial condition, results of operations and cash flows in accordance with U.S. GAAP.
-
Control Remediation Continued
Remediation efforts during the quarter included updates to information-technology and security controls and software workflows intended to improve vendor-billing accuracy and segregate duties among accounting personnel.
-
Reverse Stock Split Implemented
The company implemented a 1-for-22 reverse stock split effective July 16, 2026, as part of its efforts to maintain compliance with Nasdaq’s bid-price requirement.
What to watch
-
Material Internal-Control Weaknesses
As of June 30, 2026, management concluded that disclosure controls and procedures were not effective because of material weaknesses involving insufficient segregation of duties and inadequate depth of in-house accounting personnel for complex transactions.
-
Continued Nasdaq Delisting Risk
The Nasdaq Panel’s exception requires the company to maintain a closing bid price of at least $1.00 on each trading day through December 7, 2026; failure to do so could lead to suspension or delisting.
-
Potential Immediate MVLS Delisting
The company’s market value of listed securities was below the $5 million threshold as of the filing date. If the amended MVLS Requirement becomes effective, remaining below $5 million for 30 consecutive business days could trigger immediate suspension and delisting without a typical cure period.
-
Reverse-Split Liquidity Risk
The 1-for-22 reverse stock split may adversely affect trading liquidity and does not guarantee continued compliance with Nasdaq’s $1.00 bid-price requirement or the terms of the exception.
-
Remediation Not Yet Complete
Management stated that remediation controls cannot be considered effective until they operate for a sufficient period and are validated through testing, indicating that the material weaknesses remained unresolved as of the filing.
Management's outlook
The provided 10-Q text contains no quantitative revenue or EPS outlook and does not provide explicit financial guidance. The filing discusses Nasdaq compliance through December 7, 2026, but this is not operating guidance.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.